HYPEREOSINOPHILIC SYNDROME
Clinical trials for HYPEREOSINOPHILIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new HYPEREOSINOPHILIC SYNDROME trials appear
Sign up with your email to follow new studies for HYPEREOSINOPHILIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer drug shows promise in taming rare blood disorder
Disease control OngoingThis study tests whether the drug imatinib (Gleevec) can safely lower high levels of eosinophils (a type of white blood cell) in people with a rare condition called hypereosinophilic syndrome. About 70 participants with the myeloid form or those who didn't respond to steroids wil…
Matched conditions: HYPEREOSINOPHILIC SYNDROME
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated May 17, 2026 02:07 UTC
-
Promising drug may tame rare blood disorder flares
Disease control OngoingThis study tests whether the drug benralizumab can prevent or delay flare-ups in people with hypereosinophilic syndrome (HES), a rare condition where too many eosinophils (a type of white blood cell) cause damage to organs. About 134 participants aged 12 and older will receive ei…
Matched conditions: HYPEREOSINOPHILIC SYNDROME
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 07, 2026 18:38 UTC